The Bitget hacker resumed transferring stolen cryptocurrency, moving $19.48 million in 52 transactions between October 21 and 24, mostly in Bitcoin. These transfers went to new wallets, suggesting an attempt to obscure the funds' trail amid the $388 million exchange breach. While no laundering services have been identified yet, the hacker still holds over $240 million in various cryptocurrencies. The breach, one of 2026's largest, highlights ongoing challenges in recovering stolen crypto despite blockchain transparency.
The Bitget hacker moved $19.48 million in 52 transactions as of late October 2026, continuing efforts to launder stolen cryptocurrency. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 24, 2026 20:01 WIB: out of 50 major cryptocurrencies, 5 rose and 43 fell. Notable movers include EOS at Rp12,649 with an 8.13% gain and a typical hold time of 87 days, EGLD at Rp60,783 down 7.38% with 91% sell order activity, and ONE at Rp24 down 7.12% with 97% buy order activity and a typical hold time of 153 days.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
